In 1993, my father died of lung cancer in India. During the years I watched him suffer with the disease, I decided that I would join pharmaceutical industry after my PhD to develop drugs (particularly aimed at treating cancer) and help improve the lives of patients.
Mohan Bangalore
Senior Director and Site Head, Wyeth
In 1993, my father died of lung cancer in India. During the years I watched him suffer with the disease, I decided that I would join pharmaceutical industry after my PhD to develop drugs (particularly aimed at treating cancer) and help improve the lives of patients. While at GlaxoSmithKline, I helped set up oncology clinical trials in India and China for Tykerb (lapatinib), which is now on the market for treatment of breast cancer. It was gratifying to see the drug I worked on help cancer patients. That moment was decisive, as it exemplifies our ability to improve patients' lives. The experience also opened the door for me to India and China clinical operations.
My major accomplishment at Wyeth has been the establishment of the India Clinical Research Center (ICRC) in Bangalore, through a novel partnership with Accenture. Today, ICRC has some 160 team members supporting core clinical functions such as clinical writing, statistical programming, medical research support, document quality, document technology, and clinical administrative data support. I also provide administrative and operational oversight for ICRC, and identify opportunities across functions and develop strategic solutions with stakeholders.
I look forward to developing new outsourcing models and creating innovative ways for sponsors and service providers to collaborate. One thing I know is that I will continue to make significant contributions to global clinical operations in the pharmaceutical industry. I see myself becoming an industry leader in clinical outsourcing with a special focus on India and China clinical operations.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.